Abstract library

24 results for "Landoni".
#2856 Pattern of Disease Recurrence and Treatment after Radical Surgery for Nonfunctioning Pancreatic Neuroendocrine Tumors (NF-PanNET)
Introduction: The risk of recurrence after radical surgery performed for pancreatic neuroendocrine tumors (PanNET) is reported between 10 and 30%. Nowadays, no adjuvant therapy is recommended for these patients and specific treatments are offered only when recurrence occurs. Nevertheless, among the available systemic and locoregional treatments, there are no specific recommendations on which the best option could be for treating recurrent disease.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Surgical treatment and Ablative Therapies
Presenting Author: MD Valentina Andreasi
#2923 Interim Analysis of Prospective Evaluation of the Management of Sporadic Nonfunctioning Asymptomatic Pancreatic Neuroendocrine Neoplasms ≤ 2 cm (ASPEN Study)
Introduction: Guidelines recommend a watchful strategy for small, incidental, nonfunctioning pancreatic neuroendocrine neoplasms (NF-PanNEN).
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Dr, PhD Stefano Partelli
#3007 An mRNA-based Classifier Identifies PanNETs with Different Clinicopathological Characteristics
Introduction: Pancreatic neuroendocrine tumors (PanNETs) are a heterogeneous group of neoplasms that varies from indolent to highly aggressive diseases. Previous studies have suggested alterations of ATRX/DAXX as biomarkers of dismal prognosis, yet inconclusive data (especially in the metastatic setting) prevent those biomarkers to be used as routine clinical tests.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - Genetics, epigenetics, miRNAs, Omics
Presenting Author: Dr Caterina Vicentini
#3014 The Number of Positive Nodes Accurately Predicts Recurrence after Distal Pancreatectomy for Nonfunctioning Neuroendocrine Neoplasms
Introduction: The most appropriate staging system of metastatic lymph nodes (N) for resected pancreatic neuroendocrine tumors (PanNETs) remains unclear, especially regarding those resected by distal pancreatectomy (DP).
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Surgical treatment and Ablative Therapies
Presenting Author: Dr. Giovanni Guarneri
#3069 Functioning Pancreatic Neuroendocrine Tumors (F-pNETs): The Experience of a Tertiary Care Center of Pancreatic Surgery
Introduction: Surgery represents the optimal treatment of F-pNETs, especially if performed in high volume centers of pancreatic surgery.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Surgical treatment and Ablative Therapies
Presenting Author: Chiara Nessi
Authors: Nessi C, Lenzi S, Landoni L, Bianchi B, ...
#1165 Discrepancy Between Radiologic and Pathologic Measurements in Pancreatic Neuroendocrine Tumors: A Retrospective Study on 199 Patients
Introduction: Preoperative radiologic size of pancreatic neuroendocrine tumors (PNET) is a crucial parameter in selection of appropriate treatment especially for incidentally discovered lesions (
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Surgical treatment
Presenting Author: MD Anna Malpaga
Keywords: size NET
#1174 Long-Term Follow-Up of Resected Small (< 2 Cm) Asymptomatic Sporadic Non-Functioning Pancreatic Neuroendocrine Tumors: Correlation Between Type of Resection, Histopathologic Features, and Outcome
Introduction: The surgical management of small, incidentally found sporadic non-functioning pancreatic neuroendocrine tumors (NF-PNET) is controversial
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Surgical treatment
Presenting Author: MD Anna Malpaga
Keywords: small
#1381 [18F]FDG-PET/CT as a Predictive Tool for Response to Chemotherapy and Everolimus Treatment in Patientes with Pancreatic Neuroendocrine Tumour
Introduction: The predictive role of 18F-FDG-PET/CT (FP) in neuroendocrine tumours is debated.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: MD Silvia Ortolani
#1383 [18F]FDG-PET/CT Heterogeneity in Patients with Metastatic, Well-Differentiated Pancreatic Neuroendocrine Tumours
Introduction: 18F-FDG-PET/CT (FP) often shows an heterogeneous pattern of positivity in patients (P) with pancreatic neuroendocrine tumours (PanNETs).
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: MD Silvia Ortolani
#1396 3-Drugs Chemotherapy Regimen for G3 PanNENs with Ki67 below 55%: Single Institution Experience
Introduction: To date no standard regimen of chemotherapy (CTH) is universally approved for advanced pancreatic neuroendocrine neoplasms (PanNENs) with Ki67
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Medical treatment - Chemotherapy
Presenting Author: MD Elisabetta Grego